Showing posts with label 2017/WHO guidelines on testing for chronic HBV and HCV infection. Show all posts
Showing posts with label 2017/WHO guidelines on testing for chronic HBV and HCV infection. Show all posts

Thursday, November 2, 2017

BMC Supplement: “Testing for chronic hepatitis B and C – a global perspective.”

Open Access
Volume 17 Supplement 1
Testing for chronic hepatitis B and C – a global perspective
By Sonjelle Shilton | 02 Nov, 2017

Dear colleagues,
I am pleased to share this link to the BMC Infectious Diseases supplement, “Testing for chronic hepatitis B and C – a global perspective.”

This supplement, timed to coincide with the 2017 World Hepatitis Summit currently ongoing in Brazil, includes important articles relating to the WHO 2017 Guidelines on hepatitis B and C testing, provides a host of information regarding the current hepatitis B and C space and recommends next steps that we can take as a global health community to tackle these diseases. More specifically, the supplement presents research on the diagnostic accuracy of hepatitis B and C testing (including the use of dried blood spots), a target product profile for optimising diagnosis of viraemic HCV infection in low- and middle-income countries, economic evaluations of testing methods, ways forward to reaching equitable hepatitis B and C testing globally, and much more.

As FIND - together with partners such as WHO and others - continues to contribute to hepatitis C elimination through our HEAD*-Start project, we look forward to participating in an ongoing dialogue with the global health diagnostic community on challenges and lessons learned within this disease space.

*Hepatitis c Elimination through Access to Diagnostics
On behalf of Francesco Marinucci, Head of FIND HCV/HIV

Published on: 1 November 2017
BMC Infectious Diseases supplement, “Testing for chronic hepatitis B and C – a global perspective.” (external URL)

Friday, April 21, 2017

New report halves the number of people infected with hepatitis C worldwide

World Health Organization: WHO - Global hepatitis report, 2017

Press Release
New WHO data reveal an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

New report halves the number of people infected with hepatitis C worldwide
Apr. 21, 2017 , 5:30 AM
A new World Health Organization (WHO) report chops the estimated number of people around the world living with the liver-damaging hepatitis C virus (HCV) in half—but the drop has nothing to do with the recent advent of powerful drugs that cure the disease for most everyone.

WHO’s Global Hepatitis Report estimates that 71 million people in 2015 were living with HCV, down from an earlier estimate of 130 million to 150 million. As the report explains, the dramatic drop occurred primarily because of tests that measured HCV’s genetic material, RNA, in people. Previous epidemiological surveys tested whether people had antibodies against the virus, which is less precise.

The report estimates that 257 million people are infected with hepatitis B virus (HBV), a number very close to previous estimates. Although HBV and HCV are unrelated, they both persist for decades, often without a person’s knowledge, and both can ultimately cause cirrhosis or liver cancer. Together, the viruses killed 1.34 million people in 2015, which the report notes is comparable to deaths from tuberculosis and higher than those from HIV/AIDS.
Continue reading....

Monday, March 13, 2017

Opening remarks at the 60th session of the Commission on Narcotic Drugs

Opening remarks at the 60th session of the Commission on Narcotic Drugs
Dr Margaret Chan
Director-General of the World Health Organization

Vienna, Austria
13 March 2017

Ambassador Bente Angell-Hansen, Chair of the Commission on Narcotic Drugs, Mr Fedotov, Executive Director of UNODC, Mr Sipp, President of INCB, heads of agencies, honourable ministers, representatives of government, youth, civil society organizations, and foundations, ladies and gentlemen,

I welcome the opportunity to address this 60th session of the Commission on Narcotic Drugs. It is truly a great pleasure and good opportunity to meet a lot of old friends.

WHO respects the mandate of the Commission as the central UN policy-making body on narcotic drugs, working to oversee application of the three narcotics conventions. Allow me to quote the comment from the youth leader "Health is at the centre of the response". Thank you

As a public health agency, WHO is committed to continue to play its role in addressing the critical public health elements of the world drug problem. WHO’s treaty-based obligation is undertaken by the WHO Expert Committee on Drug Dependence.

This long-standing Expert Committee keeps psychoactive substances under constant review, balancing their potential for abuse against evidence of a known and unique therapeutic benefit.

The UN Office on Drugs and Crime is the leading agency directly responsible for combatting the world drug problem. WHO places particular importance on our joint work on the treatment of drug dependence and care of drug users.

In fact, WHO guidelines and the harm reduction package of interventions, set out in a joint WHO/UNODC/UNAIDS technical guide, are the principal tools used by countries that have adopted a public health approach to the harms caused by drug use.

Last month, WHO and UNODC signed a memorandum of understanding that opens up a new and stronger level of structured and productive collaboration between our two agencies. Both agencies would like to see more drug users channelled through the public health system instead of through the courts and the criminal justice system.

WHO is pleased that the outcome document of last year’s UN General Assembly special session on the world drug problem shows commitment to drug policies that give prominence to public health needs and solutions.

In the context of comprehensive and balanced efforts to reduce the demand for drugs, the outcome document gives attention to prevention of drug use and recovery-oriented treatment as well as to measures aimed at minimizing the adverse public health and social consequences of drug use, including programmes that rely on medication-assisted therapies and the exchange of injection equipment. In other words, in the WHO terminology: harm reduction.

The outcome document further recognizes the huge problem caused by HIV, viral hepatitis, and other blood-borne infectious diseases that can be transmitted by injecting drug use.

It also addresses the medical needs of drug users, including treatment with antiretroviral therapy for people infected with HIV, and the use of the newer therapeutic regimens that can cure hepatitis C. This is very important. It makes a difference between life and death.

The outcome document includes well-worded recommendations to assist countries in improving access to controlled essential medicines for use in patient care, for example, to relieve pain in cancer patients.

It shows a strong commitment to help countries remove the many barriers, ranging from legislation policies to prices, which limit access to controlled but essential medicines.

Taking the right actions has become even more important with recent World Health Assembly resolutions on palliative care and epilepsy that mandate improved access to controlled medicines.

Ladies and gentlemen,

We must never forget that the ultimate objective of drug control policies is to save lives. WHO estimates that drug use is responsible for around half a million deaths each year, but this figure represents only a small part of the harm caused by the world drug problem.

In some ways, the situation is getting worse, not better. Many countries are experiencing a crisis of health emergencies and deaths from drug overdoses.

Nearly everyone in this room will know parents, or will have read about parents, who have a child with a drug problem. These parents want their child in treatment, not in jail. It is good to see so many items on your agenda that address strategies for preventing drug use, especially in youth.

As countries and international agencies continue to grapple with the world drug problem in its many dimensions, WHO urges that policies be based on the medical and scientific evidence, and not on emotions or ideology.

Rest assured that WHO will continue to work on public health dimensions of the world drug problem in collaboration with relevant UN agencies, including UNODC and other partners, and keep these efforts high on the agenda in forthcoming sessions of our governing bodies.

I wish you a most productive meeting.

Thank you.

Monday, February 20, 2017

February 2017 - WHO guidelines on testing for chronic HBV and HCV infection

Publication details
Number of pages: 204
Publication date: February 2017
Languages: English
ISBN: 978-92-4-154998-1

Guidelines on hepatitis B and C testing

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviours and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination.

These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.